Povidone-Iodine

證據等級: L5

預測適應症: 10 個

Povidone-Iodine: From Topical Antiseptic to Ventilator-Associated Pneumonia Prevention

One-Sentence Summary

Povidone-iodine (PVP-I) is a broad-spectrum topical antiseptic; it is not currently marketed or ARTG-registered in Australia and has no formally recorded “original indication” in this evidence pack. Of ten TxGNN-predicted new uses, the strongest evidence-backed candidate is Pneumonia — specifically nasal/oropharyngeal decontamination to prevent ventilator-associated pneumonia (VAP) — supported by 35 clinical trials and 20 publications, including a Cochrane systematic review and a completed Phase 2/3 RCT.

Quick Overview

Item	Content
Original Indication	Not formally recorded — PVP-I is a well-known topical/mucosal antiseptic, no systemic indication on file
Predicted New Indication	Pneumonia (ventilator-associated pneumonia prevention)
TxGNN Prediction Score	80.50%
Evidence Level	L2
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (flagged as a data gap). Based on known pharmacological information, povidone-iodine is a broad-spectrum iodophor antiseptic with established bactericidal, fungicidal and virucidal activity (including against SARS-CoV-2, MRSA, influenza and other respiratory pathogens), applied topically to skin and mucous membranes.

The predicted new use is not systemic treatment of established pneumonia, but topical decontamination of the nasal and oropharyngeal cavities in mechanically ventilated or high-aspiration-risk patients. Since the nasopharynx and oral cavity act as a reservoir seeding micro-aspiration into the lungs, reducing local microbial and viral burden with PVP-I is a mechanistically plausible strategy for lowering VAP incidence — an application consistent with its long-standing use in surgical-site and mucosal antisepsis, rather than a novel systemic pharmacology.

This is a prevention/infection-control mechanism rather than treatment of active pneumonia, and the evidence base (below) supports it accordingly.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT04364802	Phase 2	Completed	98	Intranasal PVP-I prophylaxis in front-line healthcare personnel and inpatients during SARS-CoV-2 pandemic
NCT05895773	Phase 2/3	Completed	78	Nasal + oropharyngeal PVP-I with glycyrrhizin to reduce ventilator-associated respiratory infection
NCT00950027	Phase 3	Terminated	179	Multicentre double-blind RCT of oropharyngeal PVP-I decontamination vs placebo for VAP in head trauma/cerebral haemorrhage patients
NCT04517188	Phase 4	Unknown	40	Halodine nasal antiseptic (PVP-I) evaluated for nasopharyngeal SARS-CoV-2 viral shedding
NCT05214196	Phase 4	Completed	75	Oral antiseptics (incl. PVP-I) reduced intraoral SARS-CoV-2 viral load
NCT04721626	N/A	Completed	25	Perioperative topical antiseptic bundle reduced surgical site infection risk in head and neck cancer surgery, with oral microbiome monitoring
NCT04449965	Early Phase 1	Terminated	5	Topical PVP-I rinses/gargles for mild-moderate COVID-19; terminated early, limited data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33538761	2021	RCT	JAMA Otolaryngology–Head & Neck Surgery	Nasopharyngeal PVP-I mouthwash/gargle/nasal spray reduced nasopharyngeal viral load in COVID-19 patients
39803048	2024	Crossover trial	Cureus	Novel toothbrushing method with PVP-I/moisturising gel mixture aimed at reducing aspiration pneumonia risk
37215234	2023	Systematic Review & Meta-analysis	Archives of Academic Emergency Medicine	Oral care with PVP-I in the prevention of ventilator-associated pneumonia in ICU patients
27778318	2016	Cochrane Systematic Review	Cochrane Database of Systematic Reviews	Oral hygiene care (including antiseptics) to prevent ventilator-associated pneumonia in critically ill patients
24346519	2014	Review	Critical Care Medicine	Rethinking the benefits of povidone-iodine for oropharyngeal decontamination in VAP prevention
35594333	2022	Narrative Review	Annals of Medicine	Repurposing PVP-I to reduce SARS-CoV-2 infection/transmission risk, including antiviral mechanisms and safety
39179488	2025	Network Meta-analysis	Australian Critical Care	Comparative efficacy/safety of mouthwash solutions (incl. PVP-I) on ventilator-related outcomes and mortality in ICU patients
36973223	2023	Cohort	Clinical Otolaryngology	Nasal lavage with PVP-I reduced nasopharyngeal SARS-CoV-2 viral load in vivo
36058840	2023	Cohort	Enfermedades Infecciosas y Microbiología Clínica	Mouth rinses with PVP-I and hydrogen peroxide evaluated in COVID-19 patients
32520599	2020	Review	Ear, Nose & Throat Journal	Safety review of PVP-I use in the sinonasal and oral cavities during the COVID-19 era

Australia Market Information

Povidone-iodine currently has no ARTG entries and is not marketed in Australia under this evidence pack’s records, so no product-level table can be produced.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 2–4 studies plus a Cochrane systematic review support topical PVP-I nasal/oropharyngeal decontamination for reducing VAP and respiratory pathogen burden, but results are mixed (e.g. NCT00950027 terminated) and no Australian regulatory or safety data exist for this drug, so guardrails are warranted before clinical adoption.

To proceed, the following is needed:

TGA-approved Product Information / warnings and contraindications (currently a blocking data gap — no ARTG entry exists)
Formal mechanism-of-action documentation from DrugBank or equivalent source
A defined clinical protocol (concentration, frequency, patient population) specific to VAP prophylaxis, since existing trials use heterogeneous regimens
Note: two other candidates in this evidence pack — peritonitis (L3, Research Question) and appendicitis (L2, Proceed with Guardrails) — reflect PVP-I’s established role as a surgical/peritoneal lavage antiseptic and may warrant separate evaluation.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.